World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
63580
World Ranking
6901
National Ranking
262

Kim N. Chi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kim N. Chi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 629 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kim N. Chi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kim N. Chi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kim N. Chi is affiliated with the BC Cancer Agency in Canada and has an extensive research profile focused primarily on medical and oncological sciences. Their work spans multiple related subfields including pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, oncology, cancer research, and molecular biology.

Their research centers on several main topics, most notably prostate cancer treatment and research, radiopharmaceutical chemistry and applications, prostate cancer diagnosis and treatment, PARP inhibition in cancer therapy, multiple myeloma research and treatments, testicular diseases and treatments, and sarcoma diagnosis and treatment.

Frequent collaborators in their research include Fred Saad, Lucia Nappi, Christian Kollmannsberger, Gerhardt Attard, and Neil Fleshner.

Kim N. Chi has published in a variety of journals, with frequent contributions to:

  • European Urology
  • Canadian Urological Association Journal
  • Scientific Reports
  • Cancer Research
  • Journal of Clinical Oncology

Key papers authored or co-authored by Kim N. Chi include:

  • "Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer" (2023, Journal of Clinical Oncology)
  • "Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial" (2023, The Lancet Oncology)
  • "Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)" (2024, Radiology)
  • "Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors" (2020, European Urology)
  • "Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the "ideal" patient" (2020, Cancer Medicine)

Best Publications

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

    Karim Fizazi;Nam Phuong Tran;Luis Fein;Nobuaki Matsubara

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Stephen Begbie

  • Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

    Kim N. Chi;Neeraj Agarwal;Anders Bjartell;Byung Ha Chung

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

    Karim Fizazi;Nam Phuong Tran;Luis Fein;Nobuaki Matsubara

  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

    David A. Quigley;Ha X. Dang;Shuang G. Zhao;Paul Lloyd

  • Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

    Rahul Aggarwal;Jiaoti Huang;Joshi J. Alumkal;Li Zhang

  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer

    Arun A Azad;Stanislav V Volik;Alexander W Wyatt;Anne Haegert

  • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

    Matti Annala;Matti Annala;Gillian Vandekerkhove;Daniel Khalaf;Sinja Taavitsainen

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

    Alexander W Wyatt;Matti Annala;Rahul Aggarwal;Kevin Beja

  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

    K.L. Noonan;S. North;R.L. Bitting;A.J. Armstrong

Frequent Co-Authors

Martin E. Gleave
Martin E. Gleave University of British Columbia
Alexander W. Wyatt
Alexander W. Wyatt University of British Columbia
Fred Saad
Fred Saad University of Montreal
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Eric J. Small
Eric J. Small University of California, San Francisco
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Cora N. Sternberg
Cora N. Sternberg Cornell University
Celestia S. Higano
Celestia S. Higano University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in the healthcare field can provide flexible and practical options for aspiring professionals. Online degrees are increasingly popular for those managing work, family, or other commitments alongside their studies.

Advanced nursing degrees, like the most affordable dnp programs, allow registered nurses to gain the skills necessary for leadership, education, and executive roles. Similarly, a online pharmd programs offers a flexible route for professionals aiming to become licensed pharmacists, combining rigorous curriculum with the convenience of online learning.

Beyond direct patient care roles, there is significant demand in health data management. HIM programs prepare students to manage patient records, ensure security, and lead healthcare IT systems.

For those interested in the business and administrative side of medicine, short-term medical billing and coding cost courses make it possible to quickly enter the workforce or supplement your existing healthcare career.

Best Scientists Citing Kim N. Chi

Trending Scientists

Recently Published Articles